glipizide has been researched along with Renal Insufficiency, Chronic in 2 studies
Glipizide: An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.
glipizide : An N-sulfonylurea that is glyburide in which the (5-chloro-2-methoxybenzoyl group is replaced by a (5-methylpyrazin-2-yl)carbonyl group. An oral hypoglycemic agent, it is used in the treatment of type 2 diabetes mellitus.
Renal Insufficiency, Chronic: Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)
| Excerpt | Relevance | Reference |
|---|---|---|
| " There was a lower incidence of symptomatic hypoglycemia adverse events (AEs) with sitagliptin versus glipizide (6." | 2.78 | Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. ( Arjona Ferreira, JC; Barzilai, N; Goldstein, BJ; Golm, GT; Guo, H; Kaufman, KD; Marre, M; Sisk, CM, 2013) |
| "Glipizide treatment was initiated at 2." | 2.73 | Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. ( Amatruda, JM; Arjona Ferreira, JC; Chan, JC; Davies, MJ; Gonzalez, E; Kaufman, KD; Scott, R; Sheng, D; Stein, PP; Williams-Herman, D, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, JC | 1 |
| Scott, R | 1 |
| Arjona Ferreira, JC | 2 |
| Sheng, D | 1 |
| Gonzalez, E | 1 |
| Davies, MJ | 1 |
| Stein, PP | 1 |
| Kaufman, KD | 2 |
| Amatruda, JM | 1 |
| Williams-Herman, D | 1 |
| Marre, M | 1 |
| Barzilai, N | 1 |
| Guo, H | 1 |
| Golm, GT | 1 |
| Sisk, CM | 1 |
| Goldstein, BJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sitagliptin Study in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency[NCT00095056] | Phase 3 | 91 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency Who Have Inadequate Glycemic Control[NCT00509262] | Phase 3 | 426 participants (Actual) | Interventional | 2007-10-09 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Safety and tolerability were measured in terms of the number of patients with clinical adverse experiences (CAEs), serious CAEs, drug-related CAEs, laboratory adverse experiences (LAEs), serious LAEs, and drug-related LAEs. Drug-relationship was assessed by the study investigator according to his/her best clinical judgment. (NCT00095056)
Timeframe: Week 0 through Week 12
| Intervention | Participants (Number) | |||||
|---|---|---|---|---|---|---|
| With CAEs | With drug-related CAEs | With serious CAEs | With LAEs | With drug-related LAEs | With serious LAEs | |
| Placebo | 16 | 1 | 1 | 5 | 0 | 0 |
| Sitagliptin | 41 | 8 | 9 | 9 | 1 | 0 |
Safety and tolerability were measured in terms of the number of patients with clinical adverse experiences (CAEs), serious CAEs, drug-related CAEs, laboratory adverse experiences (LAEs), serious LAEs, and drug-related LAEs. Drug-relationship was assessed by the study investigator according to his/her best clinical judgment. (NCT00095056)
Timeframe: Week 0 through Week 54
| Intervention | Participants (Number) | |||||
|---|---|---|---|---|---|---|
| With CAEs | With drug-related CAEs | With serious CAEs | With LAEs | With drug-related LAEs | With serious LAEs | |
| Placebo | 22 | 5 | 10 | 8 | 0 | 0 |
| Sitagliptin | 50 | 8 | 20 | 15 | 2 | 0 |
(NCT00509262)
Timeframe: Baseline to Week 54
| Intervention | kg (Least Squares Mean) |
|---|---|
| Sitagliptin | -0.6 |
| Glipizide | 1.2 |
Percentage of participants with at least one symptomatic hypoglycemic adverse event, excluding data after initiation of glycemic rescue therapy. (NCT00509262)
Timeframe: Baseline up to 28 days following the last dose of study therapy
| Intervention | percentage of participants (Number) |
|---|---|
| Sitagliptin | 6.2 |
| Glipizide | 17.0 |
(NCT00509262)
Timeframe: Baseline to Week 54
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Week 54 | |
| Glipizide | 143.9 | -20.2 |
| Sitagliptin | 148.6 | -16.7 |
A1C represents percentage of glycosylated hemoglobin. (NCT00509262)
Timeframe: Baseline to Week 54
| Intervention | Percent of glycosylated hemoglobin (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Week 54 | |
| Glipizide | 7.79 | -0.62 |
| Sitagliptin | 7.76 | -0.70 |
2 trials available for glipizide and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency.
Topics: Aged; Blood Glucose; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Dose-Response Rela | 2008 |
Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency.
Topics: Body Weight; Diabetes Mellitus, Type 2; Female; Glipizide; Humans; Hypoglycemic Agents; Male; Pyrazi | 2013 |